Palisade Bio, Inc. Common Stock

PALI

...

PALI: Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Show PALI Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of PALI by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

No Whale Activity for this ticker

Institutional Holdings Dashboard

Insider Trading

Quarterly net insider trading by PALI's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

No new patents for this ticker

U.S. Patents Dashboard

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on PALI's company Twitter account

WallStreetBets

Number of mentions of PALI in WallStreetBets Daily Discussion

PALI News

Recent insights relating to PALI

CNBC Recommendations

Recent picks made for PALI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PALI

Corporate Flights

Flights by private jets registered to PALI